1 |
Akinci S, Silay K, Ulas A, et al (2014). Neutrophil to lymphocyte ratio--not an independent prognostic factor in patients with the myelodysplastic syndrome. Asian Pac J Cancer Prev, 15, 10883-5.
|
2 |
Bernasconi P, Klersy C, Boni M, et al (2005). Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution. Leukemia, 19, 1424-31.
DOI
|
3 |
Brunning RD, Orazi A, Germing U, Le Beau MM. Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow HS, Campo E, Haris LN, et al (2008). WHO classification of tumours of haemopoietic and lymphoid tissues. Lyon: International agency for research on cancer, 89.
|
4 |
Chevassut TJ, Mufti GJ (2011). The myelodysplastic syndromes. In:Hoffbrand AV, Catovsky D, Tuddenham EG, Green AR. Post graduate hematology, 6th edition, 503.
|
5 |
de Hollanda A, Beucher A, Henrion D, et al (2011). Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study. Arthritis Care Res (Hoboken), 63, 1188-94.
DOI
|
6 |
Ehsan A, Aziz M (2010). Clinico-haematological characteristics in Pakistani patients of primary myelodysplastic syndrome according to World Health Organization classification. J Coll Physicians Surg Pak, 20, 232-6.
|
7 |
Fenaux P, Haase D, Sanz GF, et al (2014). ESMO guidelines working group. Myelodysplastic syndromes: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 25, 57-69.
DOI
|
8 |
Gao S, Li Z, Fu JH, et al (2015). Decitabine in the treatment of acute myeloid leukemia and myelodysplastic syndromes, which combined with complex karyotype respectively. Asian Pac J Cancer Prev, 16, 6627-32.
DOI
|
9 |
Irfan M, Kakepoto GN, Khursheed M (1998).Primary myelodysplastic syndrome: clinical spectrum of 53 cases. J Pak Med Assoc, 48, 69-73.
|
10 |
Iglesias Gallego M, Sastre Moral JL, Gayoso Diz P, et al (2003). Incidence andcharacteristics of myelodysplastic syndromes in Ourense (Spain) between 1994-1998. Haematologica, 88, 1197-9.
|
11 |
Lau LG, Chng WJ, Liu TC, et al (2004). Clinico-pathological analysis of myelodysplastic syndrome according to French-American-British classification and international prognostic scoring system. Ann Acad Med (Singapore), 33, 589-95.
|
12 |
Malcovati L, Hellstrom-Lindberg E, Bowen D, et al (2013). Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood, 122, 2943-64.
DOI
|
13 |
Newman K, Maness-Harris L, El-Hemaidi I, Akhtari M (2012). Revisiting use of growth factors in myelodysplastic syndromes. Asian Pac J Cancer Prev, 13, 1081-91.
DOI
|
14 |
Neukirchen J, Schoonen WM, Strupp C, et al (2011). Incidence and prevalence of myelodysplastic syndromes: data from the Dusseldorf MDS-registry. Leuk Res, 35, 1591-6.
DOI
|
15 |
Schnatter AR, Glass DC, Tang G, Irons RD, Rushton L (2008). Myelodysplastic syndrome and benzene exposure among petroleum workers: an international pooled analysis. J Natl Cancer Inst, 104, 1724-37.
|
16 |
Rodrigues EF, de Souza DC, Camargo A, et al (2007). Cytogenetic biclonality in a child with hypocellular primary myelodysplastic syndrome. Cancer Genet Cytogenet, 178, 70-2.
DOI
|
17 |
Rashid A, Khurshid M, Shaikh U, Adil S (2014). Chromosomal abnormalities in primary myelodysplastic syndrome. J Coll Physicians Surg Pak, 24, 632-5.
|
18 |
Shah NM, Prajapati SG, Adesara RP, Patel AP (2009). An analysis of 30 cases of myelodysplastic syndrome. Indian J Pathol Microbiol, 52, 206-9.
DOI
|
19 |
Wang XQ (2008). Sino-US shanghai leukemia cooperative group.who classification and cytogenetic analysis of 435 cases with myelodysplastic syndrome. Zhonghua Nei Ke Za Zhi, 47, 464-7.
|